Multianalyte Assays with Algorithmic Analyses for Cancer Indications - Medicare Advantage

Covers multianalyte assays with algorithmic analyses (molecular diagnostic/prognostic/predictive tests) for cancer indications — e.g., tests referenced for bladder cancer, ovarian cancer, lung oncology, and upper gastrointestinal metaplasia/dysplasia/neoplasia. Coverage, medical necessity, frequency and exclusions are determined by applicable CMS/MAC LCDs/LCAs (MolDX), with Humana deferring to the MAC’s LCD in each jurisdiction; the provided excerpt contains no independent clinical criteria or standalone coverage guarantees.

"This document chunk does not itself state specific covered diagnoses, frequency limits, exclusions, or clinical criteria — coverage is limited to what is specified in the applicable CMS/MAC LCDs an..."

Sign up to see full coverage criteria, indications, and limitations.